JP2004527463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004527463A5 JP2004527463A5 JP2002538954A JP2002538954A JP2004527463A5 JP 2004527463 A5 JP2004527463 A5 JP 2004527463A5 JP 2002538954 A JP2002538954 A JP 2002538954A JP 2002538954 A JP2002538954 A JP 2002538954A JP 2004527463 A5 JP2004527463 A5 JP 2004527463A5
- Authority
- JP
- Japan
- Prior art keywords
- actin
- skin
- thymosin
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010085238 Actins Proteins 0.000 description 17
- 102000007469 Actins Human genes 0.000 description 17
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 13
- 230000007850 degeneration Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 102100035000 Thymosin beta-4 Human genes 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 108010079996 thymosin beta(4) Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 5
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 4
- QQKKFVXSQXUHPI-NBVRZTHBSA-N Acidissiminol epoxide Chemical compound O1C(C)(C)C1CC(O)C(/C)=C/COC(C=C1)=CC=C1CCNC(=O)C1=CC=CC=C1 QQKKFVXSQXUHPI-NBVRZTHBSA-N 0.000 description 3
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 3
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 3
- 101710138529 Depactin Proteins 0.000 description 3
- 102000004878 Gelsolin Human genes 0.000 description 3
- 108090001064 Gelsolin Proteins 0.000 description 3
- 108050001408 Profilin Proteins 0.000 description 3
- 102000011195 Profilin Human genes 0.000 description 3
- FCHAMFUEENBIDH-UHFFFAOYSA-N Severin Natural products CC1CCC2C(C)C3CCC4(O)C(CC5C4CC(O)C6CC(CCC56C)OC(=O)C)C3CN2C1 FCHAMFUEENBIDH-UHFFFAOYSA-N 0.000 description 3
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 3
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 3
- 229940087051 fragmin Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 fragmin Chemical compound 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 108090000195 villin Proteins 0.000 description 2
- 101000644420 Aplysia californica Thymosin beta Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical group SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24490100P | 2000-11-02 | 2000-11-02 | |
| PCT/US2001/042900 WO2002036143A1 (en) | 2000-11-02 | 2001-11-02 | Inhibition or reversal of skin aging by actin-sequestering peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008258792A Division JP2009046502A (ja) | 2000-11-02 | 2008-10-03 | 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004527463A JP2004527463A (ja) | 2004-09-09 |
| JP2004527463A5 true JP2004527463A5 (enExample) | 2008-06-19 |
| JP4224297B2 JP4224297B2 (ja) | 2009-02-12 |
Family
ID=22924553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002538954A Expired - Fee Related JP4224297B2 (ja) | 2000-11-02 | 2001-11-02 | アクチン隔離ペプチドによる皮膚老化の阻害又は反転 |
| JP2008258792A Pending JP2009046502A (ja) | 2000-11-02 | 2008-10-03 | 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008258792A Pending JP2009046502A (ja) | 2000-11-02 | 2008-10-03 | 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1335743B1 (enExample) |
| JP (2) | JP4224297B2 (enExample) |
| AT (1) | ATE452647T1 (enExample) |
| AU (2) | AU1351302A (enExample) |
| CA (1) | CA2426200C (enExample) |
| DE (1) | DE60140892D1 (enExample) |
| DK (1) | DK1335743T3 (enExample) |
| ES (1) | ES2338633T3 (enExample) |
| PT (1) | PT1335743E (enExample) |
| WO (1) | WO2002036143A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1100529B2 (en) | 1998-07-30 | 2010-08-25 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Thymosin beta 4 promotes wound repair |
| US6821524B2 (en) * | 2002-06-03 | 2004-11-23 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions |
| KR20070001995A (ko) * | 2004-03-05 | 2007-01-04 | 리지너크스 바이오 파마소티컬스, 인코포레이티드 | 세포외 매트릭스 축적의 치료 또는 예방법 |
| JP2009502938A (ja) | 2005-07-26 | 2009-01-29 | リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド | 鬱血性心不全が原因である組織の劣化、損傷、または破損を処置または予防する方法 |
| EP2260106A4 (en) * | 2008-03-17 | 2011-04-20 | Regenerx Biopharmaceuticals | IMPROVED BETATHYMOSINFRAGMENTS |
| US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
| KR102265430B1 (ko) | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9806632D0 (en) | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
| EP1100529B2 (en) | 1998-07-30 | 2010-08-25 | The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health | Thymosin beta 4 promotes wound repair |
-
2001
- 2001-11-02 PT PT01981902T patent/PT1335743E/pt unknown
- 2001-11-02 AU AU1351302A patent/AU1351302A/xx active Pending
- 2001-11-02 AU AU2002213513A patent/AU2002213513B2/en not_active Ceased
- 2001-11-02 DE DE60140892T patent/DE60140892D1/de not_active Expired - Lifetime
- 2001-11-02 ES ES01981902T patent/ES2338633T3/es not_active Expired - Lifetime
- 2001-11-02 EP EP01981902A patent/EP1335743B1/en not_active Expired - Lifetime
- 2001-11-02 WO PCT/US2001/042900 patent/WO2002036143A1/en not_active Ceased
- 2001-11-02 CA CA2426200A patent/CA2426200C/en not_active Expired - Fee Related
- 2001-11-02 JP JP2002538954A patent/JP4224297B2/ja not_active Expired - Fee Related
- 2001-11-02 DK DK01981902.8T patent/DK1335743T3/da active
- 2001-11-02 AT AT01981902T patent/ATE452647T1/de active
-
2008
- 2008-10-03 JP JP2008258792A patent/JP2009046502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110144020A1 (en) | Treatment of infections and other disorders | |
| JP2005502672A (ja) | サイモシンβ４、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法 | |
| WO1999006440A8 (en) | Novel synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome | |
| JP2004527463A5 (enExample) | ||
| JP2009046502A (ja) | 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用 | |
| US8399412B2 (en) | Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions | |
| EP1853293B1 (en) | Thymosin beta 4 for treating multiple sclerosis | |
| US20090053194A1 (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent | |
| JP2007521336A5 (enExample) | ||
| AU2002213513A1 (en) | Inhibition or reversal of skin aging by actin-sequestering peptides | |
| CN114080394A (zh) | 新型θ-防御素类似物 | |
| JP2004525988A5 (enExample) | ||
| MXPA03010446A (es) | Composiciones farmaceuticas a base de timosina (4 (t(4), analogos, isorformas y otros derivados para el tratamiento de epidermolisis vesicular hereditaria e indicaciones dermatologicas asociadas, y metodos para esto. | |
| AU2002309842A1 (en) | Treating epidermlyosis bullosa with thymosin beta 4 | |
| US20040170625A1 (en) | Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives | |
| WO2006076254A2 (en) | Method of treating or preventing respiratory microbial infection of respiratory tissue | |
| MXPA06006849A (en) | Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent |